Algorae Pharmaceuticals Limited

1AI

Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. The company is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.

Living Cell Technologies Limited

LCT

Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as diabetes and Parkinson's disease. The company operates in both Australia and New Zealand, being the research and development and product development into living cell technologies. The firm's product candidate includes NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. Choroid plexus cells are naturally occurring support cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT's technology IMMUPEL to protect them from attack by the immune system. The firm has completed two clinical trials of NTCELL in Parkinson's disease.

Argosy Minerals Limited

AGY

Argosy Minerals Ltd. develops and produces lithium, base metals, graphite, and related minerals. The company is headquartered in Perth, Western Australia. The firm has interest in the Rincon Lithium Project in Salta Province, Argentina and a 100% interest in the Tonopah Lithium Project in Nevada, United States. The Rincon Lithium Project comprises up to 2,794 hectares of Mining Titles and mining easement landholdings at the Salar del Rincon in Salta Province, Argentina. The Project is located in the elevated and arid Puna region of Argentina and forms part of a number of highly mineralized salars in production and development. The Company’s Tonopah Lithium Project is located within the Big Smokey Valley region in Nevada, United States, and comprises 425 claims covering an area of approximately 34.25 square kilometers (km2). The Tonopah Lithium Project is directly analogous to the neighboring Silver Peak Lithium Mine deposit model, both geologically and structurally.

Australian Pacific Coal Limited

AQC

Australian Pacific Coal Ltd. engages in the exploration, development, and production activities at the mining tenements situated in Queensland and New South Wales. The company is headquartered in Brisbane, Queensland. The Company’s principal asset is the Dartbrook Coal Mine located in the Hunter Valley, New South Wales (NSW), approximately four kilometers (km) west of Aberdeen and 10 km north-west of Muswellbrook. Dartbrook mine produces a thermal coal that is typical of the Hunter Valley with the potential to produce some semi-soft metallurgical coal. Its mining tenements in the Dartbrook Project include AUTH 256, EL 4574, EL 4575, EL 5525, CL 386, ML 1381, ML 1456, and ML 1497. In Queensland, the Company holds interests in the Matuan Downs Bentonite Project and a Joint Venture interest in tenements with Blackwood Resources Pty Ltd. The mining tenement on the Matuan Downs Bentonite Project is ML 70360. The Company’s subsidiary, Mining Investments One Pty Ltd, holds a 10% interest in each of the Blackwood Resources Pty Ltd joint venture tenements, which include EPC 1955 and EPC 1987.

Austchina Holdings Limited

AUH

AustChina Holdings Ltd. engages in developing and investing in early-stage coal exploration projects. The company is headquartered in Brisbane, Queensland. The company went IPO on 2003-03-17. The Company’s exposure in the resources and energy sectors include its Blackall Coal Project, investment interests in copper exploration and a holding in Energy from Organic Waste developer Utilitas Group Pty Ltd. The Company’s Blackall Coal Project is located approximately 130 kilometers (km) south-west of the Alpha area coal projects. The firm holds two exploration permits for coal, EPC1719 and EPC1993, located near Blackall in Central Queensland. The EPC1719 and EPC1993 comprise a single project-based administration area and are located in the north-western corner of the Blackall Coal Project near the township of Blackall and centered approximately 20 km south-east of the town. The firm holds 24.70% of Queensland based bioenergy developer Utilitas Group Pty Ltd (Utilitas), which is engaged in the biogas renewable energy sector.